12,372 trials
Anemia
Primary: Percentage of Participants Maintaining Mean Hemoglobin Concentration Within +/- 1 g/dL of Their Reference Hb and Between 10.5 and 12.5 g/dL During Efficacy Evaluation…
Psoriasis
Primary: Percentage of Participants With Success According to the Investigator Global Assessment (IGA) — 19.0; 2.3 percentage of patients — p=<0.001
Seasonal Allergic Rhinitis
Primary: Change From Baseline Over 2 Weeks in Participant-Reported Morning and Evening Reflective Total Nasal Symptom Scores (TNSS) — 7.81; 7.71; -2.85; -2.68 scores on a scale…
Polycystic Ovary Syndrome
Primary: Percentage of Participants With Ovulation Detected by Ultrasound — 52.5; 40.4 percentage of participants — p=0.3
Primary Immune Deficiency Disorder
Primary: Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008)) — 0 SBIs/subject/year
Growth Disorder · Idiopathic Short Stature
Primary: Height Velocity (Ht-V) — 12.02; 6.87 cm/year — p=<0.0001
Rheumatoid Arthritis
Primary: Number of Acute Infusion Reactions in the First 24 Hours After Oral Prednisone Pretreatment to Initial Rituximab Infusion — 50 acute infusion reactions
Influenza
Primary: Number of Participants With rtPCR-confirmed Influenza-Like Illness — 96; 138 participants
Sensorineural Hearing Loss
Primary: Speech Intelligibility — 63; 60; 59; 48 Percentage of understood word
Dry Eye Disease
Primary: Number of Participants With Ocular and Nonocular Treatment Emergent Adverse Events (TEAEs) for 1 Year — 38; 118; 40; 104 participants
Chronic Hepatitis C (CHC)
Primary: Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) — 85.7; 94.7 percentage…
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Regional Neuroblastoma
Primary: Number of Responders — 21; 11 participants — p=0.0044
Heart Failure
Primary: Freedom From System-related Complications Through 9 Months Compared to an Objective Performance Criterion — 0.932 Event-Free Probability
Psoriasis
Primary: Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque…
Hepatitis C
Primary: Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12) — 68.6; 68.9; 69.4; 52.5 percentage of participants